Nang Kuang Pharmaceutical Co., Ltd. (1752.TW)
TWD 41.8
(2.45%)
TWD 41.8
(2.45%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 227.48 Million TWD | 2641.47% |
| 2022 | 8.29 Million TWD | -92.87% |
| 2021 | 116.41 Million TWD | -29.46% |
| 2020 | 165.03 Million TWD | 92.14% |
| 2019 | 85.89 Million TWD | -71.33% |
| 2018 | 299.64 Million TWD | -31.34% |
| 2017 | 436.41 Million TWD | 5.4% |
| 2016 | 414.03 Million TWD | -11.66% |
| 2015 | 468.66 Million TWD | -43.83% |
| 2014 | 834.36 Million TWD | -1.06% |
| 2013 | 843.33 Million TWD | -15.86% |
| 2012 | 1 Billion TWD | 54.22% |
| 2011 | 649.93 Million TWD | -14.68% |
| 2010 | 761.74 Million TWD | 10.76% |
| 2009 | 687.75 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 67.33 Million TWD | -70.4% |
| 2024 Q2 | 284.3 Million TWD | 322.2% |
| 2023 Q4 | 227.48 Million TWD | -24.11% |
| 2023 Q1 | 34.56 Million TWD | 316.49% |
| 2023 FY | 227.48 Million TWD | 2641.47% |
| 2023 Q2 | -5.88 Million TWD | -117.03% |
| 2023 Q3 | 299.75 Million TWD | 5192.63% |
| 2022 Q3 | 199.21 Million TWD | -14.48% |
| 2022 FY | 8.29 Million TWD | -92.87% |
| 2022 Q4 | 8.29 Million TWD | -95.83% |
| 2022 Q2 | 232.94 Million TWD | 28.46% |
| 2022 Q1 | 181.33 Million TWD | 55.76% |
| 2021 Q2 | 74.57 Million TWD | -54.7% |
| 2021 Q3 | 226.56 Million TWD | 203.83% |
| 2021 FY | 116.41 Million TWD | -29.46% |
| 2021 Q4 | 116.41 Million TWD | -48.62% |
| 2021 Q1 | 164.59 Million TWD | -0.26% |
| 2020 Q4 | 165.03 Million TWD | -13.57% |
| 2020 Q2 | 11.27 Million TWD | -88.34% |
| 2020 FY | 165.03 Million TWD | 92.14% |
| 2020 Q3 | 190.95 Million TWD | 1593.58% |
| 2020 Q1 | 96.69 Million TWD | 12.57% |
| 2019 Q1 | 254.6 Million TWD | -15.03% |
| 2019 Q4 | 85.89 Million TWD | -54.68% |
| 2019 FY | 85.89 Million TWD | -71.33% |
| 2019 Q3 | 189.54 Million TWD | 6.99% |
| 2019 Q2 | 177.16 Million TWD | -30.42% |
| 2018 Q2 | 260.07 Million TWD | -23.58% |
| 2018 Q3 | 380.91 Million TWD | 46.46% |
| 2018 FY | 299.64 Million TWD | -31.34% |
| 2018 Q1 | 340.34 Million TWD | -22.01% |
| 2018 Q4 | 299.64 Million TWD | -21.34% |
| 2017 Q3 | 487.77 Million TWD | 72.58% |
| 2017 Q4 | 436.41 Million TWD | -10.53% |
| 2017 FY | 436.41 Million TWD | 5.4% |
| 2017 Q1 | 409.65 Million TWD | -1.06% |
| 2017 Q2 | 282.64 Million TWD | -31.01% |
| 2016 Q4 | 414.03 Million TWD | -9.01% |
| 2016 FY | 414.03 Million TWD | -11.66% |
| 2016 Q3 | 455.04 Million TWD | 38.98% |
| 2016 Q2 | 327.4 Million TWD | -26.1% |
| 2016 Q1 | 443.05 Million TWD | -5.46% |
| 2015 Q3 | 656.05 Million TWD | -28.99% |
| 2015 Q4 | 468.66 Million TWD | -28.56% |
| 2015 FY | 468.66 Million TWD | -43.83% |
| 2015 Q1 | 873.92 Million TWD | 4.74% |
| 2015 Q2 | 923.92 Million TWD | 5.72% |
| 2014 Q2 | 795.42 Million TWD | -7.04% |
| 2014 Q1 | 855.62 Million TWD | 1.46% |
| 2014 Q4 | 834.36 Million TWD | 2.44% |
| 2014 Q3 | 814.44 Million TWD | 2.39% |
| 2014 FY | 834.36 Million TWD | -1.06% |
| 2013 Q4 | 843.33 Million TWD | -8.52% |
| 2013 Q1 | 799.57 Million TWD | -20.23% |
| 2013 Q2 | 762.35 Million TWD | -4.65% |
| 2013 Q3 | 921.82 Million TWD | 20.92% |
| 2013 FY | 843.33 Million TWD | -15.86% |
| 2012 FY | 1 Billion TWD | 54.22% |
| 2012 Q1 | 766.63 Million TWD | 17.96% |
| 2012 Q4 | 1 Billion TWD | 9.11% |
| 2012 Q3 | 918.59 Million TWD | -0.55% |
| 2012 Q2 | 923.65 Million TWD | 20.48% |
| 2011 Q3 | 869.44 Million TWD | 10.43% |
| 2011 FY | 649.93 Million TWD | -14.68% |
| 2011 Q1 | 793.46 Million TWD | 4.17% |
| 2011 Q2 | 787.34 Million TWD | -0.77% |
| 2011 Q4 | 649.93 Million TWD | -25.25% |
| 2010 Q4 | 761.74 Million TWD | 0.0% |
| 2010 FY | 761.74 Million TWD | 10.76% |
| 2009 FY | 687.75 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Maxigen Biotech Inc. | -431.03 Million TWD | 152.777% |
| SciVision Biotech Inc. | -163.18 Million TWD | 239.402% |
| Bionime Corporation | 2.42 Billion TWD | 90.621% |
| Pegavision Corporation | 63.52 Million TWD | -258.118% |
| Visco Vision Inc. | 563 Million TWD | 59.594% |